Dr. Jerry L. Nadler

• 
  www.vabio.org/combination-drug-therapy-may-hold-the-key - [Cached Version]
  Published on: 5/11/2008    Last Visited: 5/11/2008  

  Jerry Nadler and Sarah Tersey and conducted at the University of Virginia.
  ...
  "We are very encouraged by the results of this study and others that indicate LSF in combination with certain peptides, or small molecules, is a potential therapy for the reversal of type 1 diabetes," said Dr. Nadler, chief science officer of DiaKine.

• 
  www.diabetes-watch-blog.com/blogs/diabetes-watch-blog.h - [Cached Version]
  Published on: 3/8/2008    Last Visited: 3/8/2008  

  "This research is exciting because it advances our knowledge of a new gene that is involved in causing Type 1 diabetes and could pave the way for new therapys to prevent or reverse this increasingly prevalent disease," said Dr. Jerry L. Nadler, who is chief of the UVa Division of Endocrinology and Metabolism.........

• 
  www.eurekalert.org/pub_releases/2008-06/evms-udc061008. - [Cached Version]
  Published on: 6/10/2008    Last Visited: 6/11/2008  

  The study tested the combination of Lisofylline (LSF), a drug that is being developed to halt immune damage to insulin producing cells, and Islet Neogenesis Associated Protein peptide (INGAP), a drug based on a naturally occurring protein produced by the pancreas. (ADA abstract number: 1620-P Unique Drug Combination for Reversal of Type 1 Diabetes, by Tersey, Carter, Kropf, Rosenberg, Nadler, available online at http://scientificsessions.diabetes.org)
  
  The study was conducted at the University of Virginia by a team of scientists led by Jerry L. Nadler, M.D.Currently Director of Endocrinology and Metabolism at the University of Virginia, Nadler will join the faculty at Eastern Virginia Medical School (EVMS) in July as chair of the Department of Internal Medicine and head of the EVMS Strelitz Diabetes Center.
  ...
  "These are very encouraging results," Nadler said."Since both LSF and INGAP are already known to be safe, we should soon be able to begin testing the combination of LSF and INGAP in the clinic as a potential therapy for Type 1 diabetes in people soon."
  
  Nadler was recruited to EVMS as part of a strategic initiative to expand the medical school's research capabilities in four areas where the state's eastern region has specific health needs and EVMS has existing research strengths, including: diabetes, cardiovascular disease, women's health/infant development, and cancer.
  ...
  Nadler's work with LSF and INGAP is exactly the kind of innovative new therapy that we want to bring to fruition.
  ...
  Dr. Nadler is DiaKine's Chief Scientific Officer.

• 
  www.virginiabusiness.com/index.php/people/article/peopl - [Cached Version]
  Published on: 8/27/2009    Last Visited: 8/27/2009  

  Dr. Jerry Nadler, named chairman of the internal medicine department at Eastern Virginia Medical School in Norfolk. Nadler had chaired the endocrinology and metabolism department at the University of Virginia Medical School. He will work to recruit top talent to EVMS to develop nationally competitive research operations. That $8 million

• 
  www.dailypress.com/news/local/norfolk/dp-local_wevms_07 - [Cached Version]
  Published on: 7/2/2008    Last Visited: 7/3/2008  

  Dr. Jerry Nadler, head of Internal Medicine, is also bringing new staff with him.
  
  By Nancy young/the Virginian-pilot July 2, 2008
  
  NORFOLK - Dr. Jerry Nadler starts Tuesday as head of Eastern Virginia Medical School's Department of Internal Medicine, bringing with him new staff and possible local clinical trials for a promising new diabetes treatment.
  
  EVMS hired Nadler away from the University of Virginia with an $8 million package in the hopes that he will bring in more in research dollars, new talent and better health care, particularly for diabetics and those with cardiovascular disease.
  
  Nadler said he was seeking funding and Food and Drug Administration approval for human tests of a treatment for Type I diabetes that has proved successful in mice.
  
  In Type I diabetes, the body's immune system mistakenly begins attacking insulin-producing cells in the pancreas that help control blood sugar.It used to be thought that the body's ability to make those cells was permanently destroyed, Nadler said, but research has shown that the body often continues to make them.
  ...
  "That trial, if you do it right, you'll probably need several million dollars," said Nadler, adding that he hopes the approval and funding will be in place to start clinical trials in 2009.
  
  Before coming to EVMS, Nadler was chief of the endocrinology and metabolism division at the University of Virginia that in 2007 was ranked eighth in the nation among comparable departments by U.S. News and World Report.
  
  "Thank you again for recruiting me," Nadler told EVMS' Board of Visitors at its June meeting.

• 
  ihub.org/forum/showthread.php?s=0fc0ef3eac7208393efbb09 - [Cached Version]
  Published on: 10/29/2007    Last Visited: 11/29/2007  

  "This research is exciting because it advances our knowledge of a new gene that is involved in causing Type 1 diabetes and could pave the way for new treatments to prevent or reverse this increasingly prevalent disease," said Dr. Jerry L. Nadler, who is chief of the UVa Division of Endocrinology and me.tabolism.

• 
  www.evmsdoctors.com/about/news/2009-06-19-diabetes-rese - [Cached Version]
  Published on: 6/19/2009    Last Visited: 8/26/2009  

  Jerry Nadler, MD NORFOLK, VA - EVMS scientists studying fat cells have demonstrated what may be a vital step in the progression of diabetes and heart disease, a discovery that could lead to the development of ground-breaking new treatments.
  
  Jerry Nadler, MD, director of the EVMS Strelitz Diabetes Center and a nationally known expert in the cardiovascular effects of diabetes, says scientists have suspected that certain fats formed by an enzyme called 12-Lipoxygenase can trigger inflammation in fat cells.
  
  "This process can then lead to the changes that cause diabetes and potentially heart disease," says Dr. Nadler, who worked in collaboration with Swarup K. Chakrabarti, PhD, a research assistant professor of internal medicine, and postdoctoral fellow Banumathi K. Cole, PhD.
  ...
  "This could form the basis of developing new treatments to prevent diabetes and related heart disease complications of diabetes and obesity," Dr. Nadler says.

• 
  asee.org/activities/organizations/fellows/list.cfm - [Cached Version]
  Last Visited: 3/7/2009  

  Gerald Nadler University of Southern California

• 
  records.uva.acalog.com/preview_entity.php?catoid=9&ent_ - [Cached Version]
  Last Visited: 5/29/2009  

  Jerry L. Nadler, M.D. (Joint appt.)

• 
  www.innovationsreport.com/html/reports/life_sciences/re - [Cached Version]
  Published on: 9/11/2007    Last Visited: 11/13/2007  

  "This research is exciting because it advances our knowledge of a new gene that is involved in causing Type 1 diabetes and could pave the way for new treatments to prevent or reverse this increasingly prevalent disease," said Dr. Jerry L. Nadler, who is chief of the UVa Division of Endocrinology and Metabolism.

Page:  1 2 3 4 5